Capricor says FDA may not convene expert panel for cell therapy
Summary by Arizona Daily Sun
2 Articles
2 Articles
All
Left
1
Center
Right
Regulatory Update on Capricor’s Deramiocel for Duchenne
Capricor Therapeutics, which received early funding from CureDuchenne, has indicated that the FDA has decided that an Advisory Committee meeting is not warranted at this time. Capricor’s Biologics License Application (BLA) remains under Priority Review with PDUFA target action date of August 31, 2025Read the full press release HEREThe post Regulatory Update on Capricor’s Deramiocel for Duchenne appeared first on CureDuchenne.
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium